Marshall Wace LLP Has $3.70 Million Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Marshall Wace LLP boosted its holdings in Emergent BioSolutions Inc. (NYSE:EBS) by 75.4% in the second quarter, Holdings Channel reports. The firm owned 542,813 shares of the biopharmaceutical company’s stock after purchasing an additional 233,341 shares during the quarter. Marshall Wace LLP’s holdings in Emergent BioSolutions were worth $3,702,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. CWM LLC grew its holdings in shares of Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 4,906 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Emergent BioSolutions in the second quarter valued at approximately $41,000. Verus Capital Partners LLC acquired a new position in shares of Emergent BioSolutions during the 2nd quarter worth approximately $68,000. Avidian Wealth Solutions LLC bought a new stake in shares of Emergent BioSolutions during the 1st quarter worth approximately $33,000. Finally, Tidal Investments LLC acquired a new stake in shares of Emergent BioSolutions in the 1st quarter valued at approximately $34,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Stock Up 8.5 %

EBS stock opened at $9.19 on Thursday. The business’s 50 day simple moving average is $8.79 and its 200 day simple moving average is $6.43. Emergent BioSolutions Inc. has a 1-year low of $1.42 and a 1-year high of $15.10. The firm has a market capitalization of $481.57 million, a PE ratio of -0.83 and a beta of 1.60. The company has a current ratio of 1.06, a quick ratio of 0.54 and a debt-to-equity ratio of 1.16.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($1.35). The company had revenue of $254.70 million during the quarter, compared to the consensus estimate of $199.47 million. Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. During the same period in the previous year, the company earned ($1.06) earnings per share. As a group, research analysts anticipate that Emergent BioSolutions Inc. will post -1.98 EPS for the current year.

Analyst Ratings Changes

EBS has been the topic of several analyst reports. Benchmark reaffirmed a “buy” rating and set a $8.00 price target on shares of Emergent BioSolutions in a research report on Friday, August 16th. Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.